Anavex Life Sciences (AVXL.OB) Files Milestone Regulatory Submission for Alzheimer’s Treatment

QualityStocks would like to highlight Anavex Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer.

In the company’s news yesterday,

Anavex Life Sciences Corp. announced that it has filed the regulatory submission for its lead compound, ANAVEX 2-73, for the treatment of Alzheimer’s disease, with the German Health Authority, BfArM, and the local Ethics Committee of Saxony.

The filing will enable the company to move forward with clinical studies for ANAVEX 2-73, and represents an integral achievement for Anavex.

“This regulatory filing marks an important milestone in the clinical development path for ANAVEX 2-73 and our strategy to aggressively complete a phase I and IIa study in healthy human volunteers and patients, respectively,” Dr. Cameron Durrant, executive chairman of Anavex stated in the press release.

The company will commence phase I dosing of healthy human volunteers with ANAVEX 2-73 in the near future; and a phase IIa study in patients with Alzheimer’s and Mild Cognitive Impairment may provide efficacy data and additional safety data, and is currently scheduled to commence in mid 2011.

“Our extensive pre-clinical program for ANAVEX 2-73 and the data generated so far offers the possibility of excellent safety and tolerability and encouraging signs of potential efficacy,” added Dr. Durrant.

Anavex is a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.